View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsBiomind Labs 将来の成長Future 基準チェック /06現在、 Biomind Labsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長24.2%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jan 28Biomind Labs Inc. announced that it expects to receive CAD 2.52 million in fundingBiomind Labs Inc. announced a non-brokered private placement of up to 28,000,000 units at a price of CAD 0.09 per unit for gross proceeds of up to CAD 2,520,000 on January 27, 2026. Each unit will be composed of one common share and one common share purchase warrant. Each warrant will entitle the holder thereof to acquire one common share at a price of CAD 0.12for a period of 24 months following the completion of the offering. The offering is expected to close on or about February 6, 2026, and is subject to customary closing conditions, including all necessary regulatory approvals. Securities issued under the offering will be subject to a statutory hold period of four months and one day from the date of issuance. The company may also pay finders' fees to certain eligible finders in accordance with applicable securities laws and the policies of CBOE Canada.お知らせ • Dec 11Biomind Labs Inc., Annual General Meeting, Feb 04, 2026Biomind Labs Inc., Annual General Meeting, Feb 04, 2026.お知らせ • Nov 19Biomind Labs Inc. Appoints Scott Ackerman as an Independent Director of the Board of Directors, and as an Independent Member of the Audit CommitteeBiomind Labs Inc. announced that Scott Ackerman has been appointed as an independent director of the Board of Directors of the Company, and as an independent member of the Company's Audit Committee. Mr. Ackerman is the CEO of Emprise Capital Corp., a private merchant bank providing restructuring services to public companies for over 20 years, and is also a director, senior officer, and chair of a number of audit committees for several Canadian listed public companies.お知らせ • Jul 19Biomind Labs Inc. Announces the Decision to Advance A New Phase II Clinical TrialBiomind Labs Inc. announced the decision to advance a new Phase II clinical trial. This decision follows new and unexpected findings from a pre-clinical study of its proprietary compound 3,4,5-trimethoxyphenethylamine-based BMND06. The toxicological studies reveal that the BMND06 candidate is physiologically safe, exhibiting low acute and chronic oral toxicity with no mutagenic effects. The primary objective was to establish a starting safe dose for the first-in-human trial and evaluate the potential toxicity of BMND06. In addition to in vivo studies, in vitro assays surprisingly demonstrated that BMND06 significantly reduces LPS (lipopolysaccharide)-induced IL-6 (interleukin-6) levels in various colon cancer cell lines, outperforming dexamethasone-a commonly used anti-inflammatory corticosteroid-by fivefold in reducing IL-6 induction caused by LPS. Obesity is the accumulation of abnormal or excessive fat that can interfere with maintaining optimal health. Excess macronutrients in adipose tissue stimulate the release of inflammatory mediators such as tumor necrosis factor-alpha (TNF-a) and interleukin 6 (IL-6), while reducing adiponectin production, leading to a pro-inflammatory state and oxidative stress. Elevated IL-6 levels prompt the liver to synthesize and secrete C-reactive protein (CRP). As a risk factor, inflammation is a key mechanism in the development of cardiovascular diseases, including coagulation disorders, atherosclerosis, metabolic syndrome, insulin resistance, and diabetes mellitus. It is also linked to non-cardiovascular diseases such as psoriasis, depression, cancer, and renal disease. Overweight and obesity have serious social and psychological consequences for those affected. The preclinical studies have provided robust scientific evidence supporting the safety and anti-inflammatory efficacy of the active pharmaceutical ingredient of BMND06. This data justifies advancing to a Phase II New Drug Clinical Trial in humans, focusing on obesity, without the need for additional preclinical assays.Board Change • Jun 10No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Director Ben M. Illigens is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.New Risk • Dec 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.7m free cash flow). Share price has been highly volatile over the past 3 months (116% average daily change). Negative equity (-US$638k). Revenue is less than US$1m. Market cap is less than US$10m (€6.87m market cap, or US$7.48m). Minor Risk Latest financial reports are more than 6 months old (reported March 2023 fiscal period end).New Risk • Nov 08New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €6.99m (US$7.48m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.7m free cash flow). Share price has been highly volatile over the past 3 months (64% average weekly change). Negative equity (-US$638k). Revenue is less than US$1m. Market cap is less than US$10m (€6.99m market cap, or US$7.48m).お知らせ • Sep 15Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical ApplicationsBiomind Labs Inc. announced the successful completion of the first 5-Metoxi-N,N-dimethyltryptamine ("5-MeO-DMT") organic synthesis scheme. Key accomplishments of the first 5-MeO-DMT organic synthesis scheme include: Organic Synthesis Success: A pioneering organic synthesis scheme that enables the efficient production of 5-MeO-D MT freebase. This novel process ensures high purity and maintains the compound's integrity, making it suitable for pharmaceutical applications. Pharmaceutical-Grade Quality: The 5-MeO-DMD freebase produced using this new method and under Good Manufacturing Practices (GMP) meets stringent pharmaceutical standards, guaranteeing its suitability for use in the development of advanced medicines and therapies. Potential Therapeutic Applications: The availability of high-purity 5-MeO-DCT as an API paves the way for innovative research and development in various therapeutic areas. Although Biomind primarily targets the treatment of mental health disorders, such as depression and anxiety, other areas of medicine could benefit from the availability of high-purity5-MeO-D MT. Commitment to Safety and Compliance: Biomind places an emphasis on safety and compliance with regulatory standards. The Company has undertaken rigorous testing and quality control measures to ensure the levels of product safety and consistency. Additionally, the associated complexities in the authorization process, substantial expenses, and intricate logistics further compound these challenges.New Risk • Jun 14New major risk - Negative shareholders equityThe company has negative equity. Total equity: -US$638k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.7m free cash flow). Share price has been highly volatile over the past 3 months (80% average weekly change). Negative equity (-US$638k). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (€35.8m market cap, or US$38.9m).Board Change • Nov 17No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Fraser Buchan was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Apr 28No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Fraser Buchan was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Biomind Labs は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DB:3XI - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/2025N/A000N/A6/30/2025N/A000N/A3/31/2025N/A000N/A12/31/2024N/A000N/A9/30/2024N/A-100N/A6/30/2024N/A-100N/A3/31/2024N/A-1-1-1N/A12/31/2023N/A-1-1-1N/A9/30/2023N/A-1-1-1N/A6/30/2023N/A-2-1-1N/A3/31/2023N/A-3-2-2N/A12/31/2022N/A-3-2-2N/A9/30/2022N/A-4-3-3N/A6/30/2022N/A-5-3-3N/A3/31/2022N/A-5-3-3N/A12/31/2021N/A-4-2-2N/A3/31/2021N/A-37-12-12N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 3XIの予測収益成長が 貯蓄率 ( 1.6% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 3XIの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 3XIの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 3XIの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 3XIの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 3XIの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/01/29 07:59終値2026/01/27 00:00収益2025/09/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Biomind Labs Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jan 28Biomind Labs Inc. announced that it expects to receive CAD 2.52 million in fundingBiomind Labs Inc. announced a non-brokered private placement of up to 28,000,000 units at a price of CAD 0.09 per unit for gross proceeds of up to CAD 2,520,000 on January 27, 2026. Each unit will be composed of one common share and one common share purchase warrant. Each warrant will entitle the holder thereof to acquire one common share at a price of CAD 0.12for a period of 24 months following the completion of the offering. The offering is expected to close on or about February 6, 2026, and is subject to customary closing conditions, including all necessary regulatory approvals. Securities issued under the offering will be subject to a statutory hold period of four months and one day from the date of issuance. The company may also pay finders' fees to certain eligible finders in accordance with applicable securities laws and the policies of CBOE Canada.
お知らせ • Dec 11Biomind Labs Inc., Annual General Meeting, Feb 04, 2026Biomind Labs Inc., Annual General Meeting, Feb 04, 2026.
お知らせ • Nov 19Biomind Labs Inc. Appoints Scott Ackerman as an Independent Director of the Board of Directors, and as an Independent Member of the Audit CommitteeBiomind Labs Inc. announced that Scott Ackerman has been appointed as an independent director of the Board of Directors of the Company, and as an independent member of the Company's Audit Committee. Mr. Ackerman is the CEO of Emprise Capital Corp., a private merchant bank providing restructuring services to public companies for over 20 years, and is also a director, senior officer, and chair of a number of audit committees for several Canadian listed public companies.
お知らせ • Jul 19Biomind Labs Inc. Announces the Decision to Advance A New Phase II Clinical TrialBiomind Labs Inc. announced the decision to advance a new Phase II clinical trial. This decision follows new and unexpected findings from a pre-clinical study of its proprietary compound 3,4,5-trimethoxyphenethylamine-based BMND06. The toxicological studies reveal that the BMND06 candidate is physiologically safe, exhibiting low acute and chronic oral toxicity with no mutagenic effects. The primary objective was to establish a starting safe dose for the first-in-human trial and evaluate the potential toxicity of BMND06. In addition to in vivo studies, in vitro assays surprisingly demonstrated that BMND06 significantly reduces LPS (lipopolysaccharide)-induced IL-6 (interleukin-6) levels in various colon cancer cell lines, outperforming dexamethasone-a commonly used anti-inflammatory corticosteroid-by fivefold in reducing IL-6 induction caused by LPS. Obesity is the accumulation of abnormal or excessive fat that can interfere with maintaining optimal health. Excess macronutrients in adipose tissue stimulate the release of inflammatory mediators such as tumor necrosis factor-alpha (TNF-a) and interleukin 6 (IL-6), while reducing adiponectin production, leading to a pro-inflammatory state and oxidative stress. Elevated IL-6 levels prompt the liver to synthesize and secrete C-reactive protein (CRP). As a risk factor, inflammation is a key mechanism in the development of cardiovascular diseases, including coagulation disorders, atherosclerosis, metabolic syndrome, insulin resistance, and diabetes mellitus. It is also linked to non-cardiovascular diseases such as psoriasis, depression, cancer, and renal disease. Overweight and obesity have serious social and psychological consequences for those affected. The preclinical studies have provided robust scientific evidence supporting the safety and anti-inflammatory efficacy of the active pharmaceutical ingredient of BMND06. This data justifies advancing to a Phase II New Drug Clinical Trial in humans, focusing on obesity, without the need for additional preclinical assays.
Board Change • Jun 10No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Director Ben M. Illigens is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
New Risk • Dec 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.7m free cash flow). Share price has been highly volatile over the past 3 months (116% average daily change). Negative equity (-US$638k). Revenue is less than US$1m. Market cap is less than US$10m (€6.87m market cap, or US$7.48m). Minor Risk Latest financial reports are more than 6 months old (reported March 2023 fiscal period end).
New Risk • Nov 08New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €6.99m (US$7.48m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.7m free cash flow). Share price has been highly volatile over the past 3 months (64% average weekly change). Negative equity (-US$638k). Revenue is less than US$1m. Market cap is less than US$10m (€6.99m market cap, or US$7.48m).
お知らせ • Sep 15Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical ApplicationsBiomind Labs Inc. announced the successful completion of the first 5-Metoxi-N,N-dimethyltryptamine ("5-MeO-DMT") organic synthesis scheme. Key accomplishments of the first 5-MeO-DMT organic synthesis scheme include: Organic Synthesis Success: A pioneering organic synthesis scheme that enables the efficient production of 5-MeO-D MT freebase. This novel process ensures high purity and maintains the compound's integrity, making it suitable for pharmaceutical applications. Pharmaceutical-Grade Quality: The 5-MeO-DMD freebase produced using this new method and under Good Manufacturing Practices (GMP) meets stringent pharmaceutical standards, guaranteeing its suitability for use in the development of advanced medicines and therapies. Potential Therapeutic Applications: The availability of high-purity 5-MeO-DCT as an API paves the way for innovative research and development in various therapeutic areas. Although Biomind primarily targets the treatment of mental health disorders, such as depression and anxiety, other areas of medicine could benefit from the availability of high-purity5-MeO-D MT. Commitment to Safety and Compliance: Biomind places an emphasis on safety and compliance with regulatory standards. The Company has undertaken rigorous testing and quality control measures to ensure the levels of product safety and consistency. Additionally, the associated complexities in the authorization process, substantial expenses, and intricate logistics further compound these challenges.
New Risk • Jun 14New major risk - Negative shareholders equityThe company has negative equity. Total equity: -US$638k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.7m free cash flow). Share price has been highly volatile over the past 3 months (80% average weekly change). Negative equity (-US$638k). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (€35.8m market cap, or US$38.9m).
Board Change • Nov 17No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Fraser Buchan was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Apr 28No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Fraser Buchan was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.